TELA Bio's (TELA) Sell (E+) Rating Reiterated at Weiss Ratings

Key Points

• TELA Bio has had its "sell (e+)" rating reiterated by Weiss Ratings, indicating continued bearish sentiment from analysts.
• Recent reports show that institutional investors own 94.35% of TELA Bio's stock, indicating significant interest from larger financial entities.
• The company reported a loss of ($0.22) earnings per share, falling short of analyst expectations, and has set its FY 2025 guidance at negative EPS.

TELA Bio (NASDAQ:TELA - Get Free Report)'s stock had its "sell (e+)" rating restated by analysts at Weiss Ratings in a report released on Wednesday,Weiss Ratings reports.

Separately, Wall Street Zen lowered shares of TELA Bio from a "hold" rating to a "sell" rating in a report on Saturday, June 14th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average target price of $4.50.

TELA Bio Stock Performance

Shares of TELA stock opened at $1.53 on Wednesday. The business's fifty day simple moving average is $1.64 and its 200-day simple moving average is $1.52. The company has a market cap of $60.62 million, a PE ratio of -1.37 and a beta of 0.91. The company has a current ratio of 3.19, a quick ratio of 2.59 and a debt-to-equity ratio of 4.14. TELA Bio has a 12-month low of $0.86 and a 12-month high of $3.26.

TELA Bio (NASDAQ:TELA - Get Free Report) last announced its quarterly earnings data on Monday, August 11th. The company reported ($0.22) earnings per share for the quarter, missing analysts' consensus estimates of ($0.18) by ($0.04). The company had revenue of $20.20 million for the quarter, compared to analysts' expectations of $20.67 million. TELA Bio had a negative net margin of 54.12% and a negative return on equity of 329.48%. TELA Bio has set its FY 2025 guidance at EPS. Analysts expect that TELA Bio will post -1.37 earnings per share for the current fiscal year.

Institutional Trading of TELA Bio

Hedge funds have recently bought and sold shares of the business. Velan Capital Investment Management LP acquired a new position in TELA Bio during the first quarter worth $912,000. Paradigm Capital Management Inc. NY purchased a new position in TELA Bio in the 1st quarter valued at approximately $244,000. Destiny Wealth Partners LLC purchased a new position in TELA Bio in the 2nd quarter valued at approximately $102,000. Birchview Capital LP lifted its position in shares of TELA Bio by 24.0% during the 1st quarter. Birchview Capital LP now owns 155,000 shares of the company's stock worth $189,000 after purchasing an additional 30,000 shares during the last quarter. Finally, Stonepine Capital Management LLC lifted its position in shares of TELA Bio by 1.4% during the 2nd quarter. Stonepine Capital Management LLC now owns 2,083,762 shares of the company's stock worth $4,042,000 after purchasing an additional 28,537 shares during the last quarter. Institutional investors and hedge funds own 94.35% of the company's stock.

TELA Bio Company Profile

TELA Bio, Inc, a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.